Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Roswell Park Cancer Institute
St. Jude Children's Research Hospital
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Eastern Cooperative Oncology Group
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute
BriaCell Therapeutics Corporation
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Pittsburgh
Merck Sharp & Dohme LLC
City of Hope Medical Center
Case Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Emory University
National Cancer Institute (NCI)
Sanofi
University of Arkansas
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center